Dillon, Laura W., Gui, Gege, Page, Kristin M., Ravindra, Niveditha, Wong, Zoë C., Andrew, Georgia, Mukherjee, Devdeep, Zeger, Scott L., El Chaer, Firas, Spellman, Stephen, Howard, Alan, Chen, Karen, Auletta, Jeffery, Devine, Steven M., Jimenez Jimenez, Antonio Martin, De Lima, Marcos J. G., Litzow, Mark R., Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel J.
Key Points: Question: Can DNA sequencing of blood from adults with acute myeloid leukemia (AML) in first remission prior to allogeneic hematopoietic cell transplant identify patients at increased risk of subsequent relapse and death? Findings: In patients with AML in first complete remission who received a transplant from March 1, 2013, through December 31, 2017 (discovery, n = 371) or from January 1, 2018, through February 14, 2019 (validation, n = 451), the presence of residual FLT3 internal tandem duplication (FLT3-ITD) and/or NPM1 DNA variants before transplant were associated with significantly increased rates of relapse (validation cohort difference, 47%; 95% CI, 26% to 69%) and significantly worse survival (validation cohort difference, −24%; 95% CI, −39 to −9%) at 3 years, compared with those without these markers. Meaning: Among patients with AML in first remission prior to allogeneic hematopoietic cell transplant, the persistence of FLT3-ITD or NPM1 variants in the blood at an allele fraction of 0.01% or higher was associated with increased relapse and worse survival compared with those without variants detected. Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized. Objective: To determine whether DNA sequencing to identify residual variants in the blood of adults with AML in first remission before allogeneic hematopoietic cell transplant identifies patients at increased risk of relapse and poorer overall survival compared with those without these DNA variants. Design, Setting, and Participants: In this retrospective observational study, DNA sequencing was performed on pretransplant blood from patients aged 18 years or older who had undergone their first allogeneic hematopoietic cell transplant during first remission for AML associated with variants in FLT3, NPM1, IDH1, IDH2, or KIT at 1 of 111 treatment sites from 2013 through 2019. Clinical data were collected, through May 2022, by the Center for International Blood and Marrow Transplant Research. Exposure: Centralized DNA sequencing of banked pretransplant remission blood samples. Main Outcomes and Measures: The primary outcomes were overall survival and relapse. Day of transplant was considered day 0. Hazard ratios were reported using Cox proportional hazards regression models. Results: Of 1075 patients tested, 822 had FLT3 internal tandem duplication (FLT3-ITD) and/or NPM1 mutated AML (median age, 57.1 years, 54% female). Among 371 patients in the discovery cohort, the persistence of NPM1 and/or FLT3-ITD variants in the blood of 64 patients (17.3%) in remission before undergoing transplant was associated with worse outcomes after transplant (2013-2017). Similarly, of the 451 patients in the validation cohort who had undergone transplant in 2018-2019, 78 patients (17.3%) with residual NPM1 and/or FLT3-ITD variants had higher rates of relapse at 3 years (68% vs 21%; difference, 47% [95% CI, 26% to 69%]; HR, 4.32 [95% CI, 2.98 to 6.26]; P <.001) and decreased survival at 3 years (39% vs 63%; difference, −24% [2-sided 95% CI, −39% to −9%]; HR, 2.43 [95% CI, 1.71 to 3.45]; P <.001). Conclusions and Relevance: Among patients with acute myeloid leukemia in first remission prior to allogeneic hematopoietic cell transplant, the persistence of FLT3 internal tandem duplication or NPM1 variants in the blood at an allele fraction of 0.01% or higher was associated with increased relapse and worse survival compared with those without these variants. Further study is needed to determine whether routine DNA-sequencing testing for residual variants can improve outcomes for patients with acute myeloid leukemia. In this observational study, targeted deep DNA sequencing was performed to test the hypothesis that detection of specific residual AML-associated variants in the blood of patients in first remission prior to allogeneic hematopoietic cell transplant would be associated with higher rates of relapse and mortality after transplant [ABSTRACT FROM AUTHOR]